EP0773716A4 - Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen - Google Patents

Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen

Info

Publication number
EP0773716A4
EP0773716A4 EP96918369A EP96918369A EP0773716A4 EP 0773716 A4 EP0773716 A4 EP 0773716A4 EP 96918369 A EP96918369 A EP 96918369A EP 96918369 A EP96918369 A EP 96918369A EP 0773716 A4 EP0773716 A4 EP 0773716A4
Authority
EP
European Patent Office
Prior art keywords
treatment
antiviral agents
red cell
cell solutions
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918369A
Other languages
English (en)
French (fr)
Other versions
EP0773716A1 (de
Inventor
David Cook
Susan Wollowitz
Aileen Nerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,821 external-priority patent/US6171777B1/en
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of EP0773716A1 publication Critical patent/EP0773716A1/de
Publication of EP0773716A4 publication Critical patent/EP0773716A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96918369A 1995-06-07 1996-06-07 Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen Withdrawn EP0773716A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/486,821 US6171777B1 (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
US486821 1995-06-07
US476842 1995-06-07
US08/476,842 US6143490A (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
PCT/US1996/009616 WO1996039818A1 (en) 1995-06-07 1996-06-07 Treating red blood cell solutions with anti-viral agents

Publications (2)

Publication Number Publication Date
EP0773716A1 EP0773716A1 (de) 1997-05-21
EP0773716A4 true EP0773716A4 (de) 1999-08-04

Family

ID=27045311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918369A Withdrawn EP0773716A4 (de) 1995-06-07 1996-06-07 Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen

Country Status (4)

Country Link
EP (1) EP0773716A4 (de)
AU (1) AU722811B2 (de)
CA (1) CA2199731A1 (de)
WO (1) WO1996039818A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
ATE243198T1 (de) * 1997-01-06 2003-07-15 Cerus Corp Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
AU773836B2 (en) * 1997-01-06 2004-06-10 Cerus Corporation Methods and devices for the reduction of small organic compounds from blood products
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
ATE283071T1 (de) * 1997-01-06 2004-12-15 Cerus Corp Adsorbentien und geräte zur verminderung von kleinen organischen verbindungen aus blutprodukten
EP1364944A1 (de) * 1997-01-06 2003-11-26 Cerus Corporation Verbindungen mit leicht spaltbaren Bindungen zur Inaktivierung von Pathogenen
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE69826521T2 (de) * 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
CN1136042C (zh) * 1998-01-06 2004-01-28 塞鲁斯公司 降低生物组合物中化合物的流动式设备和使用方法
US7611831B2 (en) 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US6281225B1 (en) 1998-06-11 2001-08-28 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
ATE552843T1 (de) 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP1687275A4 (de) * 2003-11-21 2009-01-14 Merck & Co Inc Zur behandlung von neuropathischen schmerzen geeignete pyridin-4-ylaminverbindungen
JP5346468B2 (ja) 2004-10-29 2013-11-20 シーラス コーポレイション 赤血球不活性化プロセスのための改善されたクエンチング方法
KR101896430B1 (ko) 2008-04-09 2018-09-10 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
CN101857598B (zh) * 2010-06-25 2012-11-28 西安交通大学 一种具有降高血压活性的呋喃香豆素类化合物及其制备方法
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
CN122182613A (zh) 2015-06-26 2026-06-12 塞鲁斯公司 冷沉淀物组合物及其制备方法
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
AU2017382449B2 (en) 2016-12-23 2024-10-24 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
EP4606379A3 (de) 2017-03-03 2025-11-19 Cerus Corporation Kits und verfahren zur herstellung von pathogen-inaktivierten thrombozytenzusammensetzungen
JP7311518B2 (ja) 2017-12-29 2023-07-19 シーラス コーポレイション 生物学的流体を処理するためのシステムおよび方法
WO2020263745A1 (en) 2019-06-22 2020-12-30 Cerus Corporation Systems and methods for implementing treatment of biological fluids
CN114173842B (zh) 2019-06-22 2026-07-14 塞鲁斯公司 生物流体处理系统
JP7645203B2 (ja) 2019-06-28 2025-03-13 シーラス コーポレイション 生物学的流体処理デバイスを実装するためのシステム及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (de) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. System zur Blutbehandlung ausserhalb des Körpers
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182750A (en) * 1977-04-21 1980-01-08 Sullivan Thomas E Bloodcompatible functional polymers
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
EP0840781B1 (de) * 1995-06-07 2009-12-09 Cerus Corporation Verfahren und vorrichtungen zur entfernung von psoralenen aus blutprodukten.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (de) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. System zur Blutbehandlung ausserhalb des Körpers
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RYTIR V ET AL: "Effect of certain compounds during elimination of plasmids in Escherichia coli", FOLIA MICROBIOLOGICA, vol. 20, no. 1, 1975, Prague, Czech., pages 17 - 23, XP002101363 *
See also references of WO9639818A1 *

Also Published As

Publication number Publication date
WO1996039818A1 (en) 1996-12-19
AU722811B2 (en) 2000-08-10
EP0773716A1 (de) 1997-05-21
CA2199731A1 (en) 1996-12-19
AU6104996A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
OA08617A (fr) Inhibiteurs de métalloendopeptidase neutre dans le traitement de l'hypertention.
FR2582947B1 (fr) Dispositif de traitement par hyperthermie
EP0667769A4 (de) Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie.
EP0831836A4 (de) Synthetische katalytisch freie-radikalfänger zur verwendung als antioxydantien zur vorbeugung und heilung von krankheiten
EP0925046A4 (de) Topische zubereitungen und verfahren zur behandlung von hämorrhoiden
MA19428A1 (fr) Gilet orthopedique de soutien et de contention dans le traitement des traumatises et des operes de l'epaule, de la ceinture scapulaire et du membre superieur
FR2586490B1 (fr) Unite de traitement d'instruction de branchement
EP0758226A4 (de) Künstliche rote blutzellen
FR2643557B1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
BR9305310A (pt) Conjunto de came e conjunto de came "S"
GB9223552D0 (en) Improvements in or relating to the treatment of effluents
EP0861082A4 (de) Therapie der gewebemembraninsuffizienz
FR2595681B1 (fr) Traitement de l'eau et analyse des sols
EP0959879A4 (de) Photodynamische therapie zur behandlung von osteosrthritis
EP0591408A4 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0752880A4 (de) Behandlung von autoimmunkrankheiten mittels orales tolerierung und/oder interferon vom type i
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
MC2246A1 (fr) Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
EP0755255A4 (de) Behandlung der toxoplasmose
MA20786A1 (fr) Traitement de liquide radio-actif
EP0800396A4 (de) Behandlung hyperandrogener zustände
FR2630099B1 (fr) Procede de traitement et de purification d'eaux
GB9216506D0 (en) Improvements in or relating to the treatment of sickle cell disease
EP0840605A4 (de) Verbindungen zur verwendung in der behandlung von neurofibromatose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19970304

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61L 2/00 A, 6A 61L 2/18 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CERUS CORPORATION

17Q First examination report despatched

Effective date: 20010319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001